Celcuity Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire•05/11/2026•16:01 ET
0
Key Highlights
- ➤REVTORPYK launched September 30; 91% of U.S. commercial and Medicare lives have coverage
- ➤78% of top 36 strategic accounts ordered REVTORPYK, representing approximately 50% of addressable patients
- ➤Third-quarter net loss widened to $73.3 million, or $1.33 per share
- ➤Cash, cash equivalents and short-term investments totaled $642.7 million; runway expected through 2029
- ➤Celcuity submitted an FDA sNDA for REVTORPYK in PIK3CA-mutant breast cancer
Expert Statements
Brian Sullivan, CEO and co-founder of Celcuity
“Our commercial and medical affairs teams have laid the foundation for a strong launch over the past few years, and their efforts are paying off.”
Brian Sullivan, CEO and co-founder of Celcuity
“Physicians are enthusiastic and eager to treat their patients with REVTORPYK, and we are pleased with their interest in getting eligible patients on treatment in the initial weeks since we launched.”
Brian Sullivan, CEO and co-founder of Celcuity
“We estimate over 90% of commercial and Medicare lives are in health plans that cover REVTORPYK.”
Brian Sullivan, CEO and co-founder of Celcuity
“The unprecedented efficacy results from the wild-type cohort of the pivotal VIKTORIA-1 study, and the preferred Category 1 recommendation in the NCCN Guidelines, provide physicians with a compelling value proposition to address a significant unmet need for the tens of thousands of patients affected each year by HR+/HER2-, PIK3CA wild-type advanced breast cancer.”
REVTORPYK became commercially available on September 30th for the treatment of patients with HR+/HER2- PIK3CA wild-type locally advanced or metastatic breast cancer
91% of U.S. commercial and Medicare lives are in health plans that cover REVTORPYK
Get started
Create a free account to read the full story.